Global Molecular Diagnostics Market Report ----------------------------------------- 2014
Executive Summary Over the years, medical science has made unprecedented progress in almost every sphere of human anatomy. In the pursuit, pathological sciences, in particular, have brought forth advancements that rendered the possibility of deploying certain tests that are performed on patient samples, including blood and tissues, in order to detect the presence of concerning physiological/pathological state, or concerning congenital abnormality. Essentially, In-vitro Diagnostics (IVD) have earned the title of silent champion of the healthcare industry since this segment influences more than half of the decision-making in the overall healthcare industry. Under this umbrella, the fastest growing segment, i.e. molecular diagnostics, involves performing analysis at the molecular level, and thereby measurement of DNA, RNA, proteins or metabolites to detect genotypes, mutations or biochemical changes, or to test for specific states of health or disease. Such diagnostic methods are capable of detecting viruses, bacteria, and parasites at a fast pace with greater sensitivity and specificity and thus, have been receiving greater inclination from physicians and affiliates. The molecular diagnostics procedures for infectious diseases including CT/NG, HPV; encompasses four major disciplines: Virology, Bacteriology, Genetics and Blood Screening. Due to certain underlying factors, the oncology segment of the market is poised to undergo noteworthy expansion in the near future and thereby driving the molecular diagnostics market on the holistic basis. As of now, the global molecular diagnostics market is characterized by growth in large value mergers and acquisitions, personalized treatment in the field of oncology and reimbursement trend. The report presents thorough analysis of the global molecular diagnostics market and its various segments and also provides detailed information pertaining to its superset market, i.e. the diagnostics and the IVD industry. It further discusses the various trends, growth drivers and challenges faced by the industry. In addition to the market contention prevalent in the global molecular diagnostics market, major industry players including Roche Holdings, Novartis, Hologic and Qiagen are profiled herein. By combining SPSS Inc. s data integration and analysis capabilities with our relevant findings, we have projected the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output.
US$ Billion US$ Million US$ Billion The global molecular diagnostics market continues to be robust due to rising incidence of CT/NG disease and favorable guidelines promoting blood screening segment Global IVD Market (2009-2013) The global IVD market rose by % to reach US$... billion in 2013. The global molecular diagnostics market increased to US$... billion in 2013, which recorded a Y-O-Y growth of % over 2012. In 2013, infectious disease testing accounted for % of the molecular diagnostic market while onco-hematology accounted for %. In 2013, the global HPV market is estimated to have reached US$... million against 2012 level of US$... million. Global CT/NG market rose to an estimated US$... million in 2013 registering growth of % over previous year. Global Molecular Diagnostics Market (2009-2013) Global CT/NG Market (2011-2015E) 2011 2012 2013 2014E 2015E
Thousand Thousand US$ Billion Other factors such as rising proportion of aged population, increasing demand for oncology diagnostics and rising incidence of diabetes are also keeping the global molecular diagnostics market buoyant Global Genetic Testing Market (2009-2013) The market for genetic testing stood at US$... billion in 2009 and is estimated to have grown to US$... billion in 2013.. In 2012, million Chlamydia cases and thousand Gonorrhoea cases were recorded in the US and the country accounts for % of the global CT/NG market. The year 2014 is likely to end with thousand tumor patients in the US and the same is expected to rise to almost thousand patients by the year 2020. In 2010, the total medical costs associated with different types of cancer in the US were estimated to be about US$... billion and the same is projected to reach US$... billion by 2020. The molecular diagnostics capacity has been on the rise as well with the number of molecular laboratories increasing from... in 2012 to in 2013. Oncology Patient Pool in the United States (2014-2018E) Rising Incidence of Chlamydia in the US (2008-2012) 2014 2015E 2016E 2017E 2018E 2008 2009 2010 2011 2012
US$ Billion Rising healthcare expenditure, rising incidence of HPV disease, growing Point-of-Care diagnostics and leaping penetration of Liquid Based Cytology Tests are the other chief factors that will drive the market World Molecular Diagnostics Market Forecast, 2013-2017F 2013 2014F 2015F 2016F 2017F The global molecular diagnostics market is forecasted to grow at a CAGR of.% and is expected to reach US$... billion by 2017. Rising demand of oncology diagnostics, waning price sensitiveness, an aging population across the OECD member countries and China, rising incidence of infectious diseases, improving global economic conditions and increased consolidation are likely to keep the global market robust in the medium term, Molecular Diagnostics growth is likely to be further fueled by rising medical costs associated with the diagnosis of various diseases which the market caters to.